Metastatic Hormone-Refractory Prostatic Adenocarcinoma Expresses Somatostatin Receptors and Is Visualized in Vivo by [111In]-labeled DTPA-d-[Phe1]-Octreotide Scintigraphy

摘要: Thirty-one patients with metastatic hormone-refractory prostatic adenocarcinoma were investigated scintigraphically the 111In-labeled somatostatin analogue [DTPA-D-Phe1]-octreotide (OctreoScan) and 99mTc-labeled HDP. In vitro receptor autoradiography was performed on biopsies obtained from eight adenocarcinoma. 30 of 31 (94%), at least one metastasis positive OctreoScan scintigraphy. Of 346 lesions detected HDP bone scintigraphy, 128 visualized technique, thus accounting for a 37% detection rate. Two uptakes could not be identified scintigraphy were, thus, assessed as false positive. The disclosed low density receptors, localized tumor cells, demonstrated autoradiography. untreated in vivo before start endocrine therapy. However, none by these technique. Positron emission tomography using [11C] methionine showed decreased uptake index lesion patient treated octreotide. It is concluded that expresses somatostain receptors both vivo. results form basis development new tool characterization treatment strategy